2025-04-02 10:08:49
Latest Post
Project award for Valiant's ransomware resilient, on-premises, key data center equipment by THDC
APSEZ handles all-time high cargo volume in Mar'25
Sandhar Ascast Pvt Ltd announces strategic acquisition of Sundaram-Clayton Ltd's High Pressure and Low Pressure Aluminium Die Casting Business at its Hosur Plant.
Lemon Tree Hotels rebrands a hotel in Pune to Keys Prima by Lemon Tree Hotels
Gabriel India Ltd completes acquisition of assets from Marelli Motherson Auto Suspension Parts Pvt Ltd
Stock Report
Gland Pharma Ltd reports Rs. 231.94 crores consolidated profit in Q3FY23
Posted On : 2023-01-23 17:53:08( TIMEZONE : IST )
Gland Pharma Limited has reported Consolidated financial results for the period ended December 31, 2022.
Financial Results (Q3 FY2023) - QoQ Comparison
The company has reported total income of Rs. 999.797 crores during the period ended December 31, 2022 as compared to Rs. 1110.028 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs. 231.949 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs. 241.242 crores for the period ended September 30, 2022.
The company has reported EPS of Rs. 14.08 for the period ended December 31, 2022 as compared to Rs. 14.65 for the period ended September 30, 2022.
| Financials | Q3 FY2023 | Q2 FY2023 | % Change |
| Total Income | ₹999.797 crs | ₹1110.028 crs |  -9.93% |
| Net Profit | ₹231.949 crs | ₹241.242 crs | -3.85% |
| EPS | ₹14.08 | ₹14.65 | -3.89% |
Financial Results (Q3 FY2023) - YoY Comparison
The company has reported total income of Rs.999.797 crores during the period ended December 31, 2022 as compared to Rs.1108.994 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.231.949 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs.273.029 crores for the period ended December 31, 2021.
The company has reported EPS of Rs.14.08 for the period ended December 31, 2022 as compared to Rs.16.62 for the period ended December 31, 2021.
| Financials | Q3 FY2023 | Q3 FY2022 | % Change |
| Total Income | ₹999.797 crs | ₹1108.994 crs | -9.85% |
| Net Profit | ₹231.949 crs | ₹273.029 crs | -15.05% |
| EPS | ₹14.08 | ₹16.62 | -15.28% |
Financial Results (9 Months Ended FY2023) - YoY Comparison
The company has reported total income of Rs.3041.114 crores during the 9 Months period ended December 31, 2022 as compared to Rs.3456.398 crores during the 9 Months period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.702.360 crores for the 9 Months period ended December 31, 2022 as against net profit / (loss) of Rs.925.762 crores for the 9 Months period ended December 31, 2021.
The company has reported EPS of Rs.42.65 for the 9 Months period ended December 31, 2022 as compared to Rs.56.41 for the 9 Months period ended December 31, 2021.
| Financials | 9 Months Ended FY2023 | 9 Months Ended FY2022 | % Change |
| Total Income | ₹3041.114 crs | ₹3456.398 crs | -12.01% |
| Net Profit | ₹702.360 crs | ₹925.762 crs | -24.13% |
| EPS | ₹42.65 | ₹56.41 | -24.39% |
Shares of Gland Pharma Limited was last trading in BSE at Rs. 1377.35 as compared to the previous close of Rs. 1386.70. The total number of shares traded during the day was 14151 in over 2435 trades.
The stock hit an intraday high of Rs. 1403.40 and intraday low of 1366.60. The net turnover during the day was Rs. 19545662.00.
